124 related articles for article (PubMed ID: 10826751)
1. Anticoagulation during use of a left ventricular assist device.
Takahama T; Kanai F; Onishi K
ASAIO J; 2000; 46(3):354-7. PubMed ID: 10826751
[TBL] [Abstract][Full Text] [Related]
2. Ideal anticoagulation for use with a left ventricular assist device.
Takahama T; Kanai F; Onishi K; Yamazaki Z; Furuse A; Yoshitake T
ASAIO J; 1995; 41(3):M779-82. PubMed ID: 8573913
[TBL] [Abstract][Full Text] [Related]
3. A thromboxane A2 synthetase inhibitor as an anticoagulant for left ventricular assist devices.
Takahama T; Kanai F; Onishi K
ASAIO J; 1997; 43(5):M452-6. PubMed ID: 9360083
[TBL] [Abstract][Full Text] [Related]
4. Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction.
Siegmund R; Boer K; Poeschel K; Wolf G; Deufel T; Kiehntopf M
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):288-93. PubMed ID: 18469550
[TBL] [Abstract][Full Text] [Related]
5. Danger of urokinase as an anticoagulant with left ventricular assist devices.
Takahama T; Kanai F; Onishi K; Yamazaki Z; Furuse A; Yoshitake T
ASAIO J; 1995; 41(3):M787-90. PubMed ID: 8573915
[TBL] [Abstract][Full Text] [Related]
6. Significance of various anticoagulation therapies during use of a left ventricular assist device.
Takahama T; Kanai F; Hiraishi M; Onishi K; Yamazaki Z; Naruse Y; Furuse A; Yoshitake T
ASAIO Trans; 1989; 35(3):426-9. PubMed ID: 2597495
[TBL] [Abstract][Full Text] [Related]
7. Long-term nonheparinized left heart bypass (LHB): centrifugal pump or roller pump.
Takahama T; Kanai F; Hiraishi M; Onishi K; Yamazaki Z; Suma K; Asano K; Kazama M
Trans Am Soc Artif Intern Organs; 1985; 31():372-6. PubMed ID: 3915619
[No Abstract] [Full Text] [Related]
8. The effects of argatroban on thrombin generation and hemostatic activation in vitro.
Tanaka KA; Szlam F; Katori N; Sato N; Vega JD; Levy JH
Anesth Analg; 2004 Nov; 99(5):1283-1289. PubMed ID: 15502018
[TBL] [Abstract][Full Text] [Related]
9. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time.
Sato K; Kawasaki T; Hisamichi N; Taniuchi Y; Hirayama F; Koshio H; Matsumoto Y
Br J Pharmacol; 1998 Jan; 123(1):92-6. PubMed ID: 9484858
[TBL] [Abstract][Full Text] [Related]
11. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation.
Nagashima H
J Biol Chem; 2002 Dec; 277(52):50439-44. PubMed ID: 12496240
[TBL] [Abstract][Full Text] [Related]
12. Argatroban anticoagulation for heparin induced thrombocytopenia in patients with ventricular assist devices.
Pappalardo F; Scandroglio AM; Potapov E; Stepanenko A; Maj G; Krabatsch T; Zangrillo A; Koster A; Hetzer R
Minerva Anestesiol; 2012 Mar; 78(3):330-5. PubMed ID: 22357371
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostatic, and endothelium-derived parameters.
Suzuki S; Matsuo T; Kobayashi H; Matsuo M; Shimamo C; Koide M; Sakamoto S
Thromb Res; 2000 May; 98(4):269-79. PubMed ID: 10822073
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban.
Kawai H; Yamamoto T; Hara H; Tamao Y
Thromb Res; 1994 May; 74(3):185-91. PubMed ID: 8042187
[TBL] [Abstract][Full Text] [Related]
15. Argatroban as a primary or secondary postoperative anticoagulant in patients implanted with ventricular assist devices.
Samuels LE; Kohout J; Casanova-Ghosh E; Hagan K; Garwood P; Ferdinand F; Goldman SM
Ann Thorac Surg; 2008 May; 85(5):1651-5. PubMed ID: 18442558
[TBL] [Abstract][Full Text] [Related]
16. Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor Argatroban.
Guy S; Kitchen S; Van Veen JJ
Br J Haematol; 2018 Feb; 180(4):594-597. PubMed ID: 27785784
[No Abstract] [Full Text] [Related]
17. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
[TBL] [Abstract][Full Text] [Related]
18. Implantation of left ventricular assist devices under extracorporeal life support in patients with heparin-induced thrombocytopenia.
Hillebrand J; Sindermann J; Schmidt C; Mesters R; Martens S; Scherer M
J Artif Organs; 2015 Dec; 18(4):291-9. PubMed ID: 26044781
[TBL] [Abstract][Full Text] [Related]
19. Combined administration of protease inhibitor and thromboxane A2 synthetase inhibitor for anticoagulation of a left ventricular assist device.
Takahama T; Kanai F; Hiraishi M; Onishi K; Yamazaki Z; Naruse Y; Furuse A; Yoshitake T
ASAIO Trans; 1990; 36(3):M141-4. PubMed ID: 2252644
[TBL] [Abstract][Full Text] [Related]
20. Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia.
Mejak B; Giacomuzzi C; Heller E; You X; Ungerleider R; Shen I; Boshkov L
J Extra Corpor Technol; 2004 Jun; 36(2):178-81. PubMed ID: 15334762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
